New mRNA RSV vaccine shows promise in early trial
NCT ID NCT07071558
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 25 times
Summary
This study tested different versions of an mRNA vaccine for RSV (a common respiratory virus) in 240 healthy adults aged 18 to 49. The goal was to check safety and how well the vaccines trigger an immune response. Each participant received one shot and was followed for about 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS IMMUNIZATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Site # 0361001
Camberwell, Victoria, 3124, Australia
-
Site # 0361002
Bayswater, Victoria, 3153, Australia
-
Site # 0361003
Wollongong, New South Wales, 2500, Australia
-
Site # 0361004
Southport, Queensland, 4215, Australia
-
Site # 0361005
Morayfield, Queensland, 4506, Australia
-
Site # 0361006
Brisbane, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.